CLEVELAND, Nov. 1, 2012 /PRNewswire-USNewswire/ -- CardioInsight Technologies Inc., the leading developer of non-invasive electrocardiographic mapping technology, announced today the appointment of Patrick J. Wethington as President & CEO.
Mr. Wethington brings more than 20 years of cross functional medical device experience in the cardiovascular industry, including sales and marketing leadership roles at Guidant, Endocardial Solutions (acquired by St. Jude Medical), and CHF Solutions (acquired by Gambro). Most recently, Mr. Wethington served as President and CEO of Hemosphere, which was recently acquired by Cryolife.
"Pat's background in electrophysiology, and his experience bringing novel products to the market will serve as important assets as CardioInsight continues to develop its ECVUE™ platform," said Jim Bullock, the Company's Chairman of the Board. "Pat has developed a track record of strong leadership throughout his career, and his addition is an important complement to the organization as we further validate ECVUE's exciting potential of unique clinical applications."
"CardioInsight's non-invasive electroanatomic mapping system continues to demonstrate unique clinical impact in the fields of electrophysiology and cardiac rhythm management," said Mr. Wethington. "The growing body of clinical data validates the platform's ability to address multiple high-value opportunities of unmet need, and I am eager to help lead the organization to commercialize these unique clinical solutions."
CardioInsight is currently conducting a limited commercial introduction of its ECVUE non-invasive cardiac mapping system in Europe, demonstrating the unique ability to simplify cardiac mapping procedures and reduce procedure times. Additionally, clinical studies are being conducted in Europe to expand the use of mapping to new applications, including cardiac resynchronization therapy (CRT) and atrial fibrillation.
About CardioInsight Technologies Inc.
CardioInsight is commercializing a revolutionary technology that non-invasively generates 3D images of the electrical activity of the heart. The images help physicians map certain heart ailments such as arrhythmias and congestive heart failure. The Company's ECVUE system non-invasively generates real-time, whole heart images of the electrical activity on the surface of the heart by combining body surface electrical data with 3D anatomical data obtained from imaging scans. It then reconstructs and displays 3D images and other useful measures of cardiac electrical activity as if the measurements were taken directly from the surface of the heart. To date, CardioInsight has completed more than 425 patient studies at leading clinical centers. These studies address a broad variety of cardiac arrhythmias, as well as cardiac resynchronization therapy for congestive heart failure, demonstrating the unique clinical value of the ECVUE system. Results of the studies have been published in leading peer-reviewed journals, and presented at international clinical conferences. The Company has received its CE Mark and markets the ECVUE system in Europe.
For more information, visit CardioInsight's website at www.cardioinsight.com, or contact us at 216-453-5950.
SOURCE CardioInsight Technologies Inc.